Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShort-Term Debt repayments
Ratios

Gain Therapeutics (GANX) Accumulated Depreciation & Amortization (2020 - 2025)

Gain Therapeutics has reported Accumulated Depreciation & Amortization over the past 6 years, most recently at $169608.0 for Q3 2025.

  • Quarterly results put Accumulated Depreciation & Amortization at $169608.0 for Q3 2025, up 39.41% from a year ago — trailing twelve months through Sep 2025 was $169608.0 (up 39.41% YoY), and the annual figure for FY2024 was $123357.0, up 32.93%.
  • Accumulated Depreciation & Amortization for Q3 2025 was $169608.0 at Gain Therapeutics, up from $159709.0 in the prior quarter.
  • Over the last five years, Accumulated Depreciation & Amortization for GANX hit a ceiling of $169608.0 in Q3 2025 and a floor of $3403.0 in Q1 2021.
  • Median Accumulated Depreciation & Amortization over the past 5 years was $71933.0 (2023), compared with a mean of $74819.4.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: increased 27.05% in 2021 and later skyrocketed 871.05% in 2022.
  • Gain Therapeutics' Accumulated Depreciation & Amortization stood at $15484.0 in 2021, then soared by 244.41% to $53329.0 in 2022, then soared by 74.01% to $92797.0 in 2023, then surged by 32.93% to $123357.0 in 2024, then soared by 37.49% to $169608.0 in 2025.
  • The last three reported values for Accumulated Depreciation & Amortization were $169608.0 (Q3 2025), $159709.0 (Q2 2025), and $136778.0 (Q1 2025) per Business Quant data.